CoChat
Sign Up
Cited by 311Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 213 of the 214 references it cites were found in a registry or an index.

Memantine for dementia.

McShane, Rupert, Westby, Maggie J, Roberts, Emmert, Minakaran, Neda, Schneider, Lon, Farrimond, Lucy E, Maayan, Nicola, Ware, Jennifer, Debarros, Jean·2019·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd003154.pub6
Open this paper in CoChat — free account

Abstract

Background Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. It is licensed for use in moderate and severe Alzheimer's disease (AD); in the USA, it is also widely used off-label for mild AD. Objectives To determine efficacy and safety of memantine for people with dementia. To assess whether memantine adds benefit for people already taking cholinesterase inhibitors (ChEIs). Search methods We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's register of trials (http://www.medicine.ox.ac.uk/alois/) up to 25 March 2018. We examined clinical trials registries, press releases and posters of memantine manufacturers; and the web sites of the FDA, EMEA and NICE. We contacted authors and companies for missing information. Selection criteria Double-blind, parallel group, placebo-controlled, randomised trials of memantine in people with dementia. Data collection and analysis We pooled and analysed data from four clinical domains across different aetiologies and severities of dementia and for AD with agitation. We assessed the impact of study duration, severity and concomitant use of ChEIs. Consequently, we restricted analyses to the licensed dose (20 mg/day or 28 mg extended release) and data at six to seven months duration of follow-up, and analysed separately results for mild and moderate-to-severe AD.We transformed results for efficacy outcomes into the difference in points on particular outcome scales. Main results Across all…

Overview

Integrity signals

Registry

Crossref · 10.1002/14651858.cd003154.pub6

Cites

213 of 213 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 92

  1. Nakamura, 2011, Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease, Japanese Journal of Geriatric Psychiatry, 22, 464
  2. Anonymous Forest press release http://ir.frx.com/phoenix.zhtml?c=83198&p=irol-newsArticle&ID=482107&highlight= (Accesed 5 April 2018)
  3. Doody RS Tariot PN Pfeiffer E Olin JT Graham SM Bell JM Meta-analysis of six month memantine clinical trials Conference Proceeding: New Clinical Drug Evaluation Unit 45 Annual Meeting. Boca Raton, Florida, June 6-9 2005 2005
  4. Bakchine, 2008, Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double-blind, placebo-controlled 6-month study, Journal of Alzheimer’s Disease, 13, 97, 10.3233/JAD-2008-13110 · DOI
  5. Bakchine, 2007, Memantine treatment in patients with mild to moderate Alzheimer’s Disease: results of a randomised, double-blind, placebo-controlled 6-month study ( (study 99679) [Corrected and republished in: J Alzheimers Dis. 2008 Feb;13(1):97-107], Journal of Alzheimer’s Disease, 11, 471, 10.3233/JAD-2007-11409 · DOI
  6. Winblad, 2007, Memantine in moderate to severe Alzheimer’s Disease: a meta-analysis of randomised clinical trials, Dementia and Geriatric Cognitive Disorders, 24, 20, 10.1159/000102568 · DOI
  7. Winblad B Jones RW Wirth Y Stöffler A Möbius HJ Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th - 20th July 2006 [poster] 2006 · DOI
  8. Ditzler, 1991, Efficacy and tolerability of memantine in patients with dementia syndrome, Arzneimittelforschung, 41, 773
  9. Dysken, 2014, Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data, Alzheimer's & Dementia, 10, 36, 10.1016/j.jalz.2013.01.014 · DOI
  10. Dysken, 2014, Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial [erratum appears in JAMA. 2014 Mar 19;311(11):1161], JAMA, 311, 33, 10.1001/jama.2013.282834 · DOI · Paper page
  11. Dysken, 2014, Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data, Alzheimer's & Dementia, 10, 36, 10.1016/j.jalz.2013.01.014 · DOI
  12. Dysken, 2014, Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial [erratum appears in JAMA 2014 Mar 19;311(11):1161], JAMA, 311, 33, 10.1001/jama.2013.282834. · DOI · Paper page
  13. Emre M and 11018 study investigators A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with PDD or DLB 9th International conference on Alzheimer's and Parkinson's disease. Prague
  14. Forest Laboratories, Inc. announces positive results of memantine study of once-daily formulation Press release
  15. Graham, 2012, Response across multiple outcome measures in patients with moderate to severe Alzheimer's disease taking extended-release memantine (28 mg, once daily), Annals of Neurology, 72, S42
  16. Tocco, 2013, Benefits of extended-release memantine in moderate-to-severe Alzheimer's Disease as a function of disease severity: post hoc analysis from a randomized trial, Annals of Neurology, Conference: 138, S92
  17. Tocco, 2013, Clinical benefits of extended-release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial, Alzheimer's & Dementia, Conference: Alz, P655, 10.1016/j.jalz.2013.05.1345 · DOI
  18. Tocco, 2011, Effects of once-daily, extended-release memantine (28 mg/day) on cognitive domains in patients with moderate to severe alzheimer's disease, Annals of Neurology, 70 Suppl 15, S54
  19. Tocco, 2012, Sustained cognitive improvement with extended-release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease, Annals of Neurology, Conference: 137, S42
  20. Tocco, 2012, Sustained cognitive improvement with extended-release memantine (28 mg, once daily) in moderate to severe alzheimer's disease, Consultant Pharmacist, Conference: Ame, 717
  21. Holland, 2013, Effect of memantine on the progression of driving impairment in patients with mild Alzheimer's disease, Journal of Nutrition, Health and Aging, Conference: 6th, 823
  22. Kitamura, 2011, Late phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease, Jpn J Geriatr Psychiat.2011, 22, 453
  23. Nakamura, 2013, Efficacy and safety of memantine in people with moderate-to-severe Alzheimer's disease: results of a pooled analysis of randomized, double-blind placebo-controlled trials in Japan, Alzheimer's & Dementia, Conference: Alz, P297, 10.1016/j.jalz.2013.05.605 · DOI
  24. Nakamura, 2016, Study of memantine hydrochloride in combination with donepezil hydrochloride in patients with moderate to severe Alzheimer’s disease - Efficacy and safety, Japanese Journal of Geriatric Medicine, 54, 1147
  25. Orgogozo JM Forette F Efficacy of memantine in mild to moderate vascular dementia (The MMM300 Trial) 6th International Stockholm/ Springfield Symposium on Advances in Alzheimer Therapy; 2000 April 5-8, Stockholm 2000
  26. Pantev, 1993, Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment, Zeitschrift fuer Gerontopsychologie und Psychiatrie, 6, 103
  27. Peskind, 2006, Memantine treatment in mild to moderate Alzheimer Disease: A 24-week randomized, controlled trial, American Journal of Geriatric Psychiatry, 14, 704, 10.1097/01.JGP.0000224350.82719.83 · DOI
  28. Winblad B Jones RW Wirth Y Stöffler A Möbius HJ Memantine in moderate to severe Alzheimer’s Disease: a meta-analysis of randomised clinical trials Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th - 20th July 2006 2006 · DOI
  29. Winblad, 2007, Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials, Dementia and Geriatric Cognitive Disorders, 24, 20, 10.1159/000102568 · DOI
  30. Winblad B Jones RW Wirth Y Stöffler A Möbius HJ English Title: Memantine in moderate to severe Alzheimer’s Disease: a meta-analysis of randomised clinical trials Poster at 10th International Conference on Alzheimer's disease and related disorders. Madrid 15th - 20th July 2006 2006 · DOI
  31. Winblad, 2007, Memantine in moderate to severe Alzheimer’s Disease: a meta-analysis of randomised clinical trials, Dementia and Geriatric Cognitive Disorders, 24, 20, 10.1159/000102568 · DOI
  32. Ferris S Clinical trial of memantine in severe Alzheimer disease: rationale and design Proceedings of the 9th Congress of the International Psychogeriatric Association, Aug 15-20 1999, Vancouver 1999
  33. Gauthier S Wirth Y Moebius HJ Positive behavioural effects of memantine treatment in patients with Alzheimer's disease IPA 12th International Congress, Stockholm, Sweden, 20-24 September 2005 2005 · DOI
  34. Reisberg B Möbius HJ Stöffler A Schmitt F Doody R Ferris S Long treatment with the NMDA antagonist memantine results of a 24 week open label extension study in moderately severe to severe Alzheimer's disease The 8th Conference on Alzheimer's disease and related disorders, July 20-25, 2002, Stockholm, Sweden 2002
  35. Reisberg B Stöffler A Ferris SH Schmitt F Doody RS A placebo controlled study of memantine in advanced Alzheimer's disease Proceedings of the 15th Annual Meeting of the American Psychiatric Association; 2001 May 5-10, New Orleans 2001
  36. Reisberg B Windscheif U Ferris SH Stöffler A Möbius HJ and the Memantine Study Group Treatment of advanced Alzheimer's disease with memantine, an NMDA antagonist: results of a 6 month multicenter randomized controlled trial Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10-14, 2000. San Juan, Puerto Rico 2000 · DOI
  37. Wimo A Winblad B Stoeffler A Wirth Y Moebius HJ Effect of long term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28-week randomized double-blind, placebo-controlled study Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25, Stockholm, Sweden 2002 Abstract No 167
  38. Gauthier, 2005, Effects of memantine on behavioural symptoms in Alzheimer's Disease patients: an analysis of the neuropsychiatric inventory (npi) data of two randomised, controlled studies, International Journal of Geriatric Psychiatry, 20, 459, 10.1002/gps.1341 · DOI
  39. Tariot, 2004, Memantine for patients with Alzheimer Disease: reply to Funicane, JAMA, 291, 1695, 10.1001/jama.291.14.1695-a · DOI
  40. Vercelletto, 2009, Efficacy and tolerability of memantine (20 mg) in behavioral variant of frontotemporal dementia: double-blind, parallel group, placebo-controlled trial, Neurology, 72, A12
  41. Xiao, 2012, Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: a 24 week double-blind, randomized, placebo-controlled study, Journal of Nutrition, Health & Aging, Conference: 5th, 855
  42. Orgogozo J Forette F Wilcock HG Moebius HG Stoeffler A Memantine in vascular dementia Journal of the Neurological Sciences. Papers from the 2nd Congress on Vascular Dementia, Salzburg, Austria, 24-27 January 2002 2002 318
  43. Wilcock G Cognitive improvement by memantine in a placebo-controlled trial in mild to moderate vascular dementia (The MMM 500 trial) 6th International Stockholm/Sprinfield symposium on advances in Alzheimer Therapy. April 5-8, 2000. Stockholm 2000
  44. Wilcock, 2000, Efficacy of memantine has been verified by two double-blind studies, Neurologie und Rehabilitation, 6, 226
  45. Wilkinson D Fox N Barkhof F Phul R Scheltens P Evaluating the effect of memantine on the rate of brain atrophy in patients with Alzheimer's disease: a multicentre imaging study using a patient enrichment strategy 14th InternationalCongress of the International Psychogeriatric Conference,Montreal
  46. Doody, 2004, Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease, Dementia and Geriatric Cognitive Disorders, 18, 227, 10.1159/000079833 · DOI · Paper page
  47. Winblad, 1999, Clinical improvement in a placebo-controlled trial with memantine in care-dependent patients with severe dementia (M-BEST), 633
  48. Winblad, 1999, Memantine in severe dementia: results of the 9M-BEST study (Benefit and Efficacy in Severely demented patients during Treatment with memantine), International Journal of Geriatric Psychiatry, 14, 135, 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0 · DOI
  49. Waldemar G Korner A Hyvarinen M Wetterberg P Lehto H Krog Josiassen M Tolerability of switching from Donepezil to Memantine treatment in patients with moderate to severe Alzheimer's disease 7th International Conference on Alzheimer's and Parkinson's disease, Sorrento 2005
  50. Bernal-Pacheco, 2010, Memantine improves ''off periods'' in patients with advanced Parkinson's disease, Movement Disorders, 25 Suppl 2, S290
  51. Cheon, 2008, The improvement of deteriorated behavior and quality of lfe in alcohol related dementia after 12 weeks of open-label memantine clinical trial., Alcoholism-Clinical and Experimental Research, 32, 181A
  52. Cummings, 2012, Extended-release memantine (28 mg, once daily) and sustained behavioral improvement: post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease, Neurology, 78, P04.197
  53. Defer, 2013, Long term treatment with memantine failed to improve cognitive function in relapsing remitting multiple sclerosis: A placebo-controlled, double-blinded, randomized study, Multiple Sclerosis (Houndmills, Basingstoke, England), Conference: 29t, 279
  54. Feldman HH Schmitt FA Olin JT Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment Alzheimer Disease and Associated Disorders 2006 263 8 · DOI
  55. Ferris, 2010, Memantine treatment benefits the language function in patients with moderate to severe Alzheimer's disease, European Journal of Neurology, 17 Suppl 3, 357
  56. Gauthie, 2010, Benefits of combination treatment in Alzheimer's disease, European Journal of Neurology, 17 Suppl 3, 354
  57. Gavrilova S Seleznyova N Kolykhalov I Proceedings of the 8th European College of Neuropharmacology Congress (ECNP); 1995 Sep 30- 0ct 4, Venice 1995
  58. Graham, 2010, Functional communication in patients with moderate Alzheimer's disease treated with memantine, European Neuropsychopharmacology, 20, S557
  59. Graham, 2010, Memantine prevents worsening across multiple domains in a trial of patients with moderate Alzheimer's disease, European Neuropsychopharmacology, 20 Suppl 3, S557
  60. Graham, 2013s, Efficacy of memantine with and without donepezil in moderate-to-severe Alzheimer's disease: pooled analysis of four randomized trials, Annals of Neurology, Conference: 138, S88
  61. Grossberg, 2010, Benefits of once-daily, extended-release memantine on caregiver distress in patients with moderate to severe Alzheimer's disease, Annals of Neurology, 68, S47
  62. Grossberg GT Manes F Allegri R Robledo LMG Benefits of extended-release memantine (28 mg, once daily) on caregiver distress: results of a multinational, double-blind, placebo-controlled trial in moderate to severe Alzheimer's disease American Journal of Geriatric Psychiatry 2010 S73 4
  63. Hendrix, 2015, Effects of add-on memantine on daily functioning in patients with moderate to severe Alzheimer's disease receiving stable donepezil treatment, Neuro-degenerative Diseases, Conference: 12t, 839
  64. Jones, 2011, Effect of memantine on key domains in patients with moderate to severe Alzheimer's disease receiving stable doses of donepezil: a pooled analysis, European Journal of Neurology, 18, 78
  65. Ladea M Sinca M Bran CM The benefits of memantine treatment on behavioral and psychotic symptoms in mild to moderate Alzheimer's disease International Journal of Neuropsychopharmacology 2010 138
  66. Li G-J Xiao S-F Li X Yang Q-M Feng L-Y Xu X-F Memantine oral solution in treatment of moderate to severe Alzheimer's disease: a multicenter, randomized, double-blind, parallel-group controlled study Chinese Journal of New Drugs and Clinical Remedies 2011 184 8
  67. Molinuevo, 2011, Effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease receiving stable doses of donepezil, European Journal of Neurology, 18, 79
  68. Peng, 2015, The clinical research of the combination use of memantine and donepezil in the treatment of moderate to severe Alzheimer's disease, Chinese Journal of Geriatric Care, 13, 75-7
  69. Rodriguez RL Haq IU Wu S Memantine for the treatment of levodopa induced dyskinesias in demented and non-demented patients with Parkinson's disease Movement Disorders. Conference: 14th International Congress of Parkinson's Disease and Movement Disorders Buenos Aires Argentina. Conference Start: 20100613 Conference End: 20100617. Conference Publication: (var.pagings)
  70. Saxton, 2009, Memantine treatment in patients with Alzheimer's Disease: neuropsychological results from an open-label, multi-center brain imaging trial, Neurology, 72, A382
  71. Tocco, 2010, Effects of memantine treatment on language abilities and functional communication in patients with moderate to severe Alzheimer's disease: a review of data, European Journal of Neurology, 17 Suppl 3, 357
  72. Tocco, 2011, Efficacy of memantine in moderate to severe Alzheimer's disease: time-to-event analysis in a pooled population, Neurodegenerative Diseases, 8 Suppl 1, A621
  73. Tocco M Hendrix S Miller LM Pejovic V Graham SM Efficacy of memantine by baseline disease severity: a pooled post-hoc analysis of trials in mild to moderate Alzheimer's disease Journal of Post-acute and Long-term Care Medicine 2011 B10 · DOI
  74. Tocco, 2012, Effects of extended-release memantine (28 mg, once daily) on language and communication abilities in a randomized trial of patients with moderate-to-severe Alzheimer's disease, Consultant Pharmacist, 27, 718
  75. Tocco, 2012, Extended-release memantine (28 mg, once daily) and sustained cognitive improvement: post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease, Journal of the American Geriatrics Society, 60, S197
  76. Wang, 2015, Clinical study of donepezil and memantine hydrochloride in the treatment of Alzheimer's disease, China Continuing Medical Education, 7, 271
  77. Weiner, 2009, Memantine treatment in patients with Alzheimer's Disease is associated with a slower right hippocampal volume loss: an open-label, multi-center trial, Neurology, 172, A150
  78. Wilkinson, 2010, Short- and long-term treatment with memantine in Alzheimer's disease, Neurobiology of Aging, 31 Suppl 1, S33
  79. Wirth, 2012, Memantine enhances autonomy in moderate to severe Alzheimer's disease patients already receiving donepezil, European Journal of Neurology, 19, 474
  80. Zheng, 2011, The efficacy and safety of combination therapy of memantine and donepezil among old Alzheimer's disease patients (Translated from Chinese), Modern Practical Medicine, 4, 415
  81. Gauthier, 2005, Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies, International Journal of Geriatric Psychiatry, 20, 459, 10.1002/gps.1341 · DOI
  82. Guy, 1976, CGI: Clinical global impressions, 217
  83. Honigfeld, 1974, History and current status of its use in pharmaco-psychiatric research, 7 Psychological, 238
  84. Kishi, 2017, Memantine for Alzheimer’s Disease: an updated systematic review and meta-analysis, Journal of Alzheimer’s Disease, 60, 401, 10.3233/JAD-170424 · DOI
  85. Matsunaga, 2015, Memantine for Alzheimer’s Disease: systematic review and meta-analysis, PLOS One, 10, e0123289. doi:1, 10.1371/journal.pone.0123289 · DOI
  86. Reisberg, 1997, Clinical global measures of dementia: position paper from the International Working group on Harmonization of Dementia Drug Guidelines, Alzheimer Disease and Associated Disorders, 11 (suppl 3), 8
  87. Schünemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  88. Schünemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  89. Kam, 1989, ADL and behaviour rating scales for the evaluation of nurses' workload in psychogeriatric nursing homes, Tijdschrift voor Gerontologie en Geriatrie, 20, 159
  90. Wilcock, 2008, Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies, Journal of Clinical Psychiatry, 69, 341, 10.4088/JCP.v69n0302 · DOI · Paper page
  91. Wimo, 1988, Evaluation of the resource utilisation and caregiver time in anti-dementia drug trials: a quantitative battery, 465
  92. Winblad, 2007, Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials, Dementia and Geriatric Cognitve Disorders, 24, 20, 10.1159/000102568 · DOI

Cited by

Sorted by citations

See all 311

Related

See all

Metadata

Authors
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J.
Affiliations
  • John Radcliffe Hospital (GB)
  • Manchester Academic Health Science Centre (GB)
  • King's College London (GB)
  • Moorfields Eye Hospital NHS Foundation Trust (GB)
  • University of Southern California (US)
  • Cochrane (GB)
  • University of Oxford (GB)
ORCID
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2019-03-20
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd003154.pub6
OpenAlex
W4211051557
Cited by
310
References
214
Citations by year
2026: 36 · 2025: 36 · 2024: 53 · 2023: 52 · 2022: 53 · 2021: 41 · 2020: 25 · 2019: 14
FWCI
5.61
Type
journal article
Language
en
Open access
closed
Locations
Cochrane Database of Systematic Reviews (publishedVersion)
Funders
National Institute for Health and Care Research (13/89/22)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
memantine, dementia, Alzheimer's disease, NMDA receptor antagonists, cholinesterase inhibitors, combination therapy, cognitive function, activities of daily living, functional status, agitation, off-label drug use, drug safety, adverse events, mild Alzheimer's disease, risk of bias, publication bias, sustained-release formulation, long-term follow-up

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review